Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1644 1645 1674 1699
This examiner grants 66% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17783229 | ANTI-PD-L1 ANTIBODY FORMULATIONS | Final Rejection | Genentech, Inc. |
| 17542138 | METHOD FOR REGENERATION OF AN OVERLOAD CHROMATOGRAPHY COLUMN | Final Rejection | Genentech, Inc. |
| 18176844 | THERAPEUTIC ANTIBODY FORMULATION | Non-Final OA | Eli Lilly and Company |
| 19248893 | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREBY | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 19217541 | PROCESS FOR REDUCING SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18105772 | Stabilized Formulations Containing Anti-IL-33 Antibodies | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18011412 | TYPE 2 CYTOKINES AS PREDICTORS OF DISEASE SEVERITY AND/OR AS THERAPEUTIC TARGETS FOR COVID-19 | Non-Final OA | University of Virginia Patent Foundation |
| 17335680 | Method for the reduction of host cell proteins in affinity chromatography | Non-Final OA | Hoffmann-La Roche Inc. |
| 18046450 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY | Final Rejection | Takeda Pharmaceutical Company Limited |
| 16817671 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK | Final Rejection | Takeda Pharmaceutical Company Limited |
| 18620109 | MULTIPLE FUNCTIONALIZED noMV CONJUGATES | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18054076 | METHODS OF TREATMENT USING ANTI-CD123 IMMUNOCONJUGATES | Final Rejection | ImmunoGen, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy